Mycobacterium Avium Complex (MAC): Symptoms, Causes & Treatment

Mycobacterium avium complex (MAC) refers to a group of slow-growing, environmental nontuberculous mycobacteria (NTM)—primarily Mycobacterium avium and M. intracellulare—that cause opportunistic infections in humans, particularly in immunocompromised individuals and those with structural lung disease.

Transmission & Epidemiology

MAC is ubiquitous in the environment—soil, water (municipal, natural), dust, aerosols. Infection is acquired via inhalation (respiratory tract) or ingestion (GI tract), not person-to-person. It is an opportunistic pathogen: disease occurs when host defenses are breached.

  • Immunocompromised hosts: Advanced HIV (CD4 <50 cells/μL), transplant recipients, immunosuppressive therapy, inherited immunodeficiencies. Disseminated MAC was an AIDS-defining illness pre-ART; now rare with early ART.
  • Structural lung disease: Bronchiectasis, COPD, cystic fibrosis, prior TB, pneumoconiosis. Causes "Lady Windermere syndrome" (middle lobe/lingula predominance in older women).
  • Other: Lymphadenitis in children (cervical nodes); skin/soft tissue infections; prosthetic joint infections.

Symptoms

Vary by syndrome:

  • Disseminated (HIV): Fever, night sweats, weight loss, fatigue, diarrhea, abdominal pain, anemia, hepatosplenomegaly. Insidious onset.
  • Pulmonary (NTM lung disease): Chronic cough, sputum, fatigue, weight loss, hemoptysis, low-grade fever. Often mimics TB or bronchiectasis exacerbation.
  • Lymphadenitis: Painless, unilateral cervical lymph node swelling in children 1–5 years.

Diagnosis

Challenging; requires integration of clinical, radiographic, and microbiologic criteria (ATS/IDSA guidelines):

  • Microbiology: Sputum AFB smear/culture (multiple samples), bronchoscopy with lavage, blood culture (disseminated), tissue biopsy with culture/histology.
  • Radiology: HRCT chest—nodules, bronchiectasis, tree-in-bud, cavities.
  • Exclusion: Rule out TB (critical), other NTM, malignancy.

Treatment

  • Disseminated MAC: Clarithromycin or azithromycin + ethambutol ± rifabutin (3-drug regimen for severe immunosuppression). Continue ≥12 months + immune recovery (CD4 >100 for >6 months on ART).
  • Pulmonary MAC: Macrolide (clarithromycin/azithromycin) + ethambutol + rifampin/rifabutin, 3x/week or daily, for 12 months post-culture conversion. Surgery for localized disease.
  • Lymphadenitis: Surgical excision ± antibiotics.

Drug interactions are significant (macrolides/rifamycins with ART, calcineurin inhibitors). Therapeutic drug monitoring and specialist management are essential.

Prognosis

Disseminated MAC in advanced HIV carries high mortality without treatment; with ART + MAC therapy, prognosis is good. Pulmonary MAC is chronic but manageable; cure rates ~50–80% with guideline therapy. Early diagnosis and expert care optimize outcomes.

Gum Disease - Related Articles